Aesthetic practices across the U.S. are reporting a surge in demand for combination treatments targeting "Ozempic face"—the hollowed, aged appearance caused by rapid weight loss from GLP-1 receptor agonists. Practices are bundling Botox or Dysport with volumizing fillers, biostimulators, and facial treatments to address dynamic lines, structural volume loss, and skin quality simultaneously.
Market
"Ozempic Face" Facials Driving Botox Boom—Practices Capitalize on GLP-1 Side Effect
Practices are bundling neuromodulators, fillers, and skin treatments to address volume loss in GLP-1 patients.
1-YEAR MOVE
ABBV▲11.6%EOLS▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
GLP-1 patients seeking facial rejuvenation are driving higher per-patient treatment frequency and bundled protocols.
This trend is driving higher average transaction values and increased per-patient visit frequency. Practices with strong filler inventory, trained staff in combination protocols, and clear before-and-after galleries showcasing Ozempic face transformations are capturing disproportionate share of this demographic. The phenomenon also highlights the importance of having robust supply agreements with manufacturers—Allergan, Galderma, and Evolus are all seeing elevated demand from practices serving this patient cohort.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.